- Home
- INMD vs TSHA Comparison
INMD vs TSHA Comparison
Compare INMD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMD
- TSHA
- Stock Information
- Founded
- INMD 2008
- TSHA 2019
- Country
- INMD Israel
- TSHA United States
- Employees
- INMD N/A
- TSHA N/A
- Industry
- INMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- INMD Health Care
- TSHA Health Care
- Exchange
- INMD Nasdaq
- TSHA Nasdaq
- Market Cap
- INMD 887.0M
- TSHA 728.4M
- IPO Year
- INMD 2019
- TSHA 2020
- Fundamental
- Price
- INMD $13.28
- TSHA $2.46
- Analyst Decision
- INMD Hold
- TSHA Strong Buy
- Analyst Count
- INMD 6
- TSHA 7
- Target Price
- INMD $17.56
- TSHA $7.57
- AVG Volume (30 Days)
- INMD 1.1M
- TSHA 4.9M
- Earning Date
- INMD 07-31-2025
- TSHA 08-11-2025
- Dividend Yield
- INMD N/A
- TSHA N/A
- EPS Growth
- INMD 8.69
- TSHA N/A
- EPS
- INMD 2.29
- TSHA N/A
- Revenue
- INMD $392,408,000.00
- TSHA $7,224,000.00
- Revenue This Year
- INMD $0.16
- TSHA N/A
- Revenue Next Year
- INMD $4.84
- TSHA N/A
- P/E Ratio
- INMD $5.79
- TSHA N/A
- Revenue Growth
- INMD N/A
- TSHA N/A
- 52 Week Low
- INMD $13.16
- TSHA $1.05
- 52 Week High
- INMD $19.85
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- INMD 33.86
- TSHA 45.90
- Support Level
- INMD $13.16
- TSHA $2.48
- Resistance Level
- INMD $13.67
- TSHA $2.66
- Average True Range (ATR)
- INMD 0.40
- TSHA 0.21
- MACD
- INMD -0.09
- TSHA -0.06
- Stochastic Oscillator
- INMD 7.23
- TSHA 10.14
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.